FDA DEVICE FACTS
SURESHOT Distal Targeting System V4.0 Trauma Interface
Smith & Nephew, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Smith & Nephew SURESHOT™ Targeting System is intended to be an intraoperative image guided localization system. It is a computer assisted orthopedic surgery tool to aid the surgeon with drill positioning for screws during intramedullary nail implantation. It provides information to the surgeon that is used to place surgical instruments during surgery utilizing intraoperatively obtained electromagnetic tracking data. The Smith & Nephew SURESHOT™ Targeting System is indicated for long bone fractures treated with intramedullary nails in which the use of stereotactic surgery may be appropriate. Summary of Pre-Clinical Testing Electromagnetic compatibility and electrical safety validation testing has been conducted on the SURESHOT™ Distal Targeting System. The subject device utilizes the same platform and tracking technology as previously cleared in K100107. The electromagnetic capability and electrical safety testing that was conducted includes. x IEC 60601-1: 2005 + A1:2012 Medical Electrical Equipment Part 1: General Requirements for Safety. x IEC 60601-1-2:2007 Class A for Emissions, Immunity for Non Life Supporting Equipment Results of the electromagnetic compatibility and electrical safety validation testing demonstrate the device is found to meet the application performance requirements to those standards. Software verification and validation testing was completed in line with FDA's guidance document entitled, “General Principles of Software Validation; Final Guidance for Industry and FDA Staff,” dated January 11, 2002. The software for this device was considered to be a “moderate” level of concern. A review of this testing has demonstrated that there are no new issues related to the safety and effectiveness of the subject device and the software will perform as intended as compared to the predicate. Clinical data was not needed to support the safety and effectiveness of the subject device. Comparison to Technological Characteristics with the Predicate Device Device comparisons described in this premarket notification demonstrated that the proposed SURESHOT™ Targeting System is equivalent to the legally marketed predicate devices cleared in the below table with regard to intended use, indications for use, and performance characteristics. The subject devices feature characteristics as previously cleared in K100107 with the primary differences being the reduced size and weight. All software features remain the same as those in K170280.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。